Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

David Lim, Rhiannon Bandiera, Elizabeth Handsley

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)

Abstract

To the Editor: The SAME study affirmed the safety and efficacy of switching between originator and biosimilars and the potential for cost savings.1 Yet the global uptake of biosimilars has been relatively slow2 due to a number of factors, including marketing suggesting that such drugs are less safe or efficacious than the originator.3 Implicated in such marketing is confusion arising from the use of
the word “interchangeable”, which is a defined term under United States legislation. The word “substitution” is used in Australia, which raises the likelihood of further confusion.
Original languageEnglish
Pages (from-to)435
Number of pages1
JournalMedical Journal of Australia
Volume215
Issue number9
DOIs
Publication statusPublished - 1 Nov 2021
Externally publishedYes

Keywords

  • Medicolegal
  • Pharmaceuticals
  • Australia

Fingerprint

Dive into the research topics of 'Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab'. Together they form a unique fingerprint.

Cite this